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        Juvenile idiopathic arthritis (JIA) is an important 
cause of short- and long-term disability. The 
term JIA encompasses a heterogeneous group of 
diseases that is classifi  ed according to three major 
types of presentation: oligoarthritis, polyarthritis, 
and systemic onset JIA (SoJIA). Each of these 
groups has diff  erent prognosis and responds dif-
ferently to available therapies (  1  –  4  ), suggesting 
that their pathogenesis is also unique. 
  Children with SoJIA usually present with 
systemic symptoms, fever and/or rash, which 
precede the development of arthritis for weeks 
or even years. Once arthritis develops, these 
patients have a highly variable disease outcome. 
The overall prognosis correlates with the persis-
tence of systemic symptoms and the number of 
joints involved 6 mo after the initial presenta-
tion (  5  –  8  ). Because of lack of success with con-
ventional treatment, up to 50% of patients with 
SoJIA continue to have active arthritis 5  –  10 yr 
after diagnosis (  2, 9, 10  ). Because long-term 
disability is directly correlated with duration of 
active disease, this group has the most severe 
outcome and thus has represented the most se-
rious challenge to pediatric rheumatologists. 
  We have recently shown that IL-1 is a major 
mediator of the infl  ammatory cascade under-
lying SoJIA (  11  ). Indeed, IL-1Ra is an eff  ective 
treatment for this disease (  11  –  14  ). IL-1 is also 
involved in the pathogenesis of familial auto-
infl  ammatory syndromes (  15  –  17  ), and blocking 
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  Systemic onset juvenile idiopathic arthritis (SoJIA) represents up to 20% of juvenile idio-
pathic arthritis. We recently reported that interleukin (IL) 1 is an important mediator of 
this disease and that IL-1 blockade induces clinical remission. However, lack of specifi  city 
of the initial systemic manifestations leads to delays in diagnosis and initiation of therapy. 
To develop a specifi  c diagnostic test, we analyzed leukocyte gene expression profi  les of 
44 pediatric SoJIA patients, 94 pediatric patients with acute viral and bacterial infections, 
38 pediatric patients with systemic lupus erythematosus (SLE), 6 patients with PAPA syn-
drome, and 39 healthy children. Statistical group comparison and class prediction identifi  ed 
genes differentially expressed in SoJIA patients compared with healthy children. These 
genes, however, were also changed in patients with acute infections and SLE. An analysis of 
signifi  cance across all diagnostic groups identifi  ed 88 SoJIA-specifi  c genes, 12 of which 
accurately classifi  ed an independent set of SoJIA patients with systemic disease. Transcripts 
that changed signifi  cantly in patients undergoing IL-1 blockade were also identifi  ed. Thus, 
leukocyte transcriptional signatures can be used to distinguish SoJIA from other febrile 
illnesses and to assess response to therapy. Availability of early diagnostic markers may 
allow prompt initiation of therapy and prevention of disabilities. 2132 DIAGNOSTIC SIGNATURES IN S  O  JIA BLOOD LEUKOCYTES | Allantaz et al.
Two additional febrile patients (Sys 85 and Sys 91; Table S1) 
were studied but later proved to have a diff  erent diagnosis. 
Samples from 11 patients with established diagnosis of SoJIA 
in whom the systemic symptoms had subsided but arthritis 
persisted (SoJIA 2) and 14 patients with no systemic symp-
toms and no arthritis at the time of blood draw (SoJIA 3) were 
also analyzed. The demographic and clinical characteristics of 
these patients are summarized in Table S1. 20 ml of blood 
was drawn after informed consent. PBMCs were isolated 
within 2  –  4 h and processed and analyzed using Aff  ymetrix 
human U133A and U133B GeneChips. 
  Blood leukocyte signatures differentiate SoJIA patients 
from healthy children 
  To identify genes whose expression would diff  erentiate   SoJIA 
patients (  n    16) from healthy controls (  n    16), statistical 
group comparisons were performed using the nonparametric 
Mann-Whitney rank test (P      0.01) and Bonferroni correc-
tion. Transcripts displaying statistically signifi  cant diff  erences 
(  n    873, 398 up-regulated and 475 down-regulated) were 
  ordered by hierarchical clustering (  Fig. 1   and Table S2, which 
is available at http://www.jem.org/cgi/content/full/jem
.20070070/DC1).   The 50 most signifi  cant genes are listed in 
IL-1 with IL-1Ra resolves the clinical symptoms of patients 
carrying mutations in the NALP3/cryopyrin gene (familial cold 
urticaria, Muckle-Wells syndrome, and NOMID/CINCA) 
(  18  –  21  ) and in the PSTPIP1 gene (PAPA syndrome, a familial 
autoinfl  ammatory disease that causes pyogenic sterile arthritis, 
pyoderma gangrenosum, and acne) (  22, 23  ). 
  The diagnosis of SoJIA is currently based on clinical fi  nd-
ings and requires the presence of arthritis (  24  ). Because this 
manifestation may take months to develop, one of the major 
remaining challenges is how to establish an early diagnosis. As 
the presenting symptoms (fever and/or rash) and laboratory 
tests (anemia, leukocytosis, thrombocytosis, and elevated 
erythrocyte sedimentation rate) are nonspecifi  c, patients un-
dergo extensive diagnostic tests and hospitalizations to exclude 
infections and malignancies. The availability of an eff  ective 
treatment fosters the need for diagnostic markers that will per-
mit the initiation of therapy at an early stage of the disease to 
minimize the risk of developing long-term disabilities. 
  We have previously shown that microarray analyses of 
blood leukocytes from children with autoimmune diseases 
can be used to assess pathogenesis (  25, 26  ). Here, we describe 
the use of blood leukocyte gene expression patterns to help 
diagnose patients with SoJIA during the systemic phase of the 
disease and to follow their response to therapy. 
    RESULTS   
  Patient characteristics 
  We analyzed 23 samples from 16 SoJIA patients display-
ing systemic symptoms (fever and/or rash) and arthritis, and 
3 SoJIA patients with only systemic symptoms (fever, rash, and/
or pericarditis) at the time of blood draw. Four patients 
(Sys12, Sys21, Sys25, and Sys51) were analyzed twice dur-
ing independent systemic fl  ares separated by 7  –  23 mo. Eight 
samples from patients with long-standing disease were ob-
tained at the time of systemic disease fl  are (fever onset     4 
preceding weeks). Five patients were newly diagnosed and 
also had had disease symptoms for no longer than 4 wk. SoJIA 
patients were predominantly females (female/male, 15/4). 
There were 10 Caucasian, 7 Hispanic, 1 Asian, and 1 African-
American children in this group. Seven patients were not 
  receiving any medication other than nonsteroidal anti-
infl  ammatory drugs at the time of blood draw. The remaining 
patients were receiving treatment with oral prednisone and/
or IV methylprednisolone pulses, methotrexate, and/or anti-
TNF therapy (Table S1, available at http://www.jem.org/cgi/
content/full/jem.20070070/DC1). However, none of the 
treated patients had received IV pulses (methylprednisolone 
or infl  iximab) for at least 4 wk before blood draw. All pa-
tients fulfi  lled the International League of Associations for 
Rheumatology clinical diagnostic criteria for SoJIA (  24  ) at 
the time of blood draw, during previous disease fl  ares, or after 
blood draw. The average time from initiation of symptoms to 
establishment of diagnosis and initiation of therapy in these 
patients was 4.8 mo (range, 6 wk  –  3 yr). If the patient with 
the longest time to diagnosis (3 yr) is excluded, the average 
time to diagnosis for the remaining patient group was 2.7 mo. 
  Figure 1.     Differential gene expression in PBMCs isolated from 
SoJIA patients and healthy controls. 17,454 genes passing the control 
criteria were tested. Genes expressed at statistically different levels between 
the two groups (P      0.01; Wilcoxon-Mann-Whitney test, Bonferroni 
correction) were rearranged by hierarchical clustering to reveal differential 
expression. Expression values are normalized per gene to the healthy 
group. Transformed expression levels are indicated by color scale, with red 
representing relative high expression and blue indicating relative low 
  expression. A list of the genes shown in this fi  gure is available in Table S2.     JEM VOL. 204, September 3, 2007 
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out cross-validation scheme.   Using this strategy, 100% of the 
healthy and 88% of the SoJIA samples were classifi  ed accu-
rately (seven were predicted accurately, and the class of the 
remaining sample was indeterminate). The ability of these 
transcripts to classify a test set composed of eight new healthy 
and eight independent SoJIA patients was tested. Using this 
approach, 100% of the patients and controls were accurately 
classifi  ed (  Fig. 2 A  , right). 
  Some of the up-regulated transcripts that best classify SoJIA 
patients encode proteins involved in heme synthesis (delta 
hemoglobin and erythroid-associated factor) and   erythrocyte-
specifi  c transcription factors (Kruppel-like factor 1), which 
could be related to the presence of nucleated erythroid pre-
cursors in SoJIA blood as described above. 
  Lack of specifi  city of the SoJIA signature 
  Children with SoJIA present with severe systemic symptoms 
(fever and rash) that usually precede the development of 
arthritis from weeks to years. Thus, the main diff  erential 
diagnosis at presentation is an infectious disease. The 50 best 
Table S2 (marked with an asterisk). The expression of some 
of these genes can be interpreted based on our current 
knowledge of the disease. Related to the frequent anemia 
and the presence of erythroblasts in the blood of these 
  patients, many erythroid lineage-specifi  c genes are found 
up-regulated. Likewise, neutrophil-specifi  c genes and genes 
that promote neutrophil survival (i.e., Foxo3a) (  27  ) are found 
overexpressed. This is consistent with the neutrophilia pre-
sent in SoJIA patients. Many of the over- and underexpressed 
genes, however, cannot be linked to a particular cell type 
or function. 
  To identify a potential diagnostic signature, a two-step class 
prediction analysis was performed. It consisted of the identi-
fi  cation of classifi  er genes and the validation of these genes in 
an independent cohort of patients and controls. 
  A subset of eight healthy volunteers and eight patients 
with an established diagnosis of SoJIA was used as a training 
set to identify the classifi  er genes (  Fig. 2 A  , left).   The 50 most 
signifi  cantly diff  erentially expressed transcripts (  Table I  ) were 
then evaluated within the same set of patients in a leave-one-
  Figure 2.     Class prediction. (A) (Left) Eight healthy and eight SoJIA samples obtained from our initial study group were used as a training set to 
generate a list of classifi  er genes displaying the best ability to discriminate patients from healthy controls. In our training set, 100% of healthy and 88% 
of SoJIA patients were classifi  ed accurately. (Right) Those classifi  er genes were then tested on a test set (eight Healthy and eight SoJIA), and 100% of 
patients were classifi  ed accurately. Expression values were normalized per gene to the healthy group. Samples and genes were arranged by hierarchical 
clustering. Transformed expression levels are indicated by color scale, with red representing relative high expression and blue indicating relative low 
  expression. The list of the genes from this fi  gure is shown in Table I. (B) Specifi  city of the SoJIA signature. The 50 best classifi  er genes from A were used 
to classify a test set of 39 healthy controls, 16 SoJIA, 31 S.   aureus  , 15 S.   pneumoniae  , 30 E.   coli  , 18 infl  uenza A, 38 SLE patients, and 6 PAPA syndrome 
patients. The number of samples within each disease group predicted as SoJIA is represented on top of the fi  gure. Genes were arranged by hierarchical 
clustering. Transformed expression levels are indicated by color scale, with red representing relative high expression and blue relative low expression.     2134 DIAGNOSTIC SIGNATURES IN S  O  JIA BLOOD LEUKOCYTES | Allantaz et al.
  Table I.  50 classifi  ers distinguishing SoJIA patients from healthy controls 
  Affymetrix ID    Gene symbol    p-value   Average 
normalized 
values in 
SoJIA 
  Gene title 
Protein biosynthesis
     200002_at RPL35 1.24E-08 0.6 ribosomal protein L35
     200089_s_at RPL4 1.48E-10 0.6 ribosomal protein L4
     200802_at SARS 2.80E-09 0.8 seryl-tRNA synthetase
     203113_s_at EEF1D 7.57E-11 0.2 eukaryotic translation elongation factor 1  (guanine nucleotide 
exchange protein)
     212018_s_at RSL1D1 2.82E-10 0.5 ribosomal L1 domain-containing 1
     221726_at RPL22 9.33E-10 0.7 ribosomal protein L22
Ubiquitination
     209845_at MKRN1 1.48E-10 4.2 makorin, ring fi  nger protein, 1
     214790_at SENP6 2.78E-09 0.5 SUMO1/sentrin specifi  c protease 6
Microtubule/Cytoskeleton
     210088_x_at MYL4 7.57E-11 9.9 myosin, light polypeptide 4, alkali; atrial, embryonic
     212878_s_at KNS2 7.57E-11 0.6 kinesin 2 60/70 kD
Transcription
     200792_at XRCC6 4.69E-09 0.7 thyroid autoantigen 70 kD (Ku antigen)
     203617_x_at ELK1 6.59E-07 1.6 ELK1, member of ETS oncogene family
     204633_s_at RPS6KA5 1.97E-08 0.6 ribosomal protein S6 kinase, 90 kD, polypeptide 5
     209430_at BTAF1 1.57E-07 0.6 BTAF1 RNA polymerase II, B-TFIID transcription factor  –  associated, 
170 kD
     210504_at KLF1 7.57E-11 6.7 Kruppel-like factor 1 (erythroid)
     214177_s_at PBXIP1 9.33E-10 0.6 pre-B cell leukemia transcription factor interacting protein 1
     217729_s_at AES 2.80E-09 0.5 amino-terminal enhancer of split
     218490_s_at ZNF302 4.68E-07 0.5 zinc fi  nger protein 302
     224518_s_at ZNF559 4.70E-08 0.5 zinc fi  nger protein 559
     226327_at ZNF507 0.000972 0.7 zinc fi  nger protein 507
     225845_at ZBTB44 1.97E-08 0.6 BTB (POZ) domain-containing 15
Metabolism
     201050_at PLD3 2.69E-05 1.4 phospholipase D3
     212174_at AK2 4.66E-09 0.7 adenylate kinase 2
     226344_at ZMAT1 4.27E-06 0.6 zinc fi  nger, matrin type 1
     235802_at PLD4 7.57E-11 0.4 chromosome 14 open reading frame 175
Immune response/Infl  ammatory response
     211734_s_at FCER1A 2.82E-10 0.3 Fc fragment of IgE, high affi  nity I, receptor for;      polypeptide
Transport
     200063_s_at NPM1 1.48E-10 0.5 nucleophosmin (nucleolar phosphoprotein B23, numatrin)
     210854_x_at SLC6A8 7.57E-11 9.2 solute carrier family 6 (neurotransmitter transporter, creatine), 
member 8
     218978_s_at SLC25A37 2.82E-10 7.5 mitochondrial solute carrier protein
Heme
     206834_at HBD 7.57E-11 36.4 hemoglobin, 
     219672_at ERAF 7.57E-11 30 erythroid associated factor
Apoptosis
     223518_at DFFA 2.82E-10 1.9 DNA fragmentation factor, 45 kD,      polypeptide
Unknown
     201537_s_at DUSP3 0.000157 1.8 dual specifi  city phosphatase 3 (vaccinia virus phosphatase VH1-
related)
     203818_s_at SF3A3 5.20E-10 0.7 splicing factor 3a, subunit 3, 60 kD
     209068_at HNRPDL 7.57E-11 0.5 heterogeneous nuclear ribonucleoprotein D  –  like
     212830_at EGFL5 4.69E-09 1.9 EGF-like domain, multiple 5JEM VOL. 204, September 3, 2007 
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  Table I.  50 classifi  ers distinguishing SoJIA patients from healthy controls (Continued) 
  Affymetrix ID    Gene symbol    p-value   Average 
normalized 
values in 
SoJIA 
  Gene title 
     213804_at INPP5B 1.06E-07 0.5 inositol polyphosphate-5-phosphatase, 75 kD
     217807_s_at GLTSCR2 7.47E-06 0.7 glioma tumor suppressor candidate region gene 2
     218877_s_at TRMT11 7.12E-08 0.5 chromosome 6 open reading frame 75
     220755_s_at C6orf48 1.48E-10 0.6 chromosome 6 open reading frame 48
     221932_s_at C14orf87 7.57E-11 10.7 chromosome 14 open reading frame 87
     223011_s_at OCIAD1 5.20E-10 0.6 OCIA domain-containing 1
     223656_s_at C1orf91 4.70E-08 1.5 hypothetical protein RP4-622L5
     225159_s_at   — 1.06E-07 0.7   — 
     225180_at TTC14 1.57E-07 0.6 tetratricopeptide repeat domain 14
     226544_x_at MUTED 2.11E-05 0.8 muted homolog (mouse)
     226680_at ZNFN1A5 3.06E-08 0.6 zinc fi  nger protein, subfamily 1A, 5
     228122_at LOC285331 0.000128 0.7 hypothetical protein LOC285331
     235587_at LOC202781 7.57E-11 0.5 hypothetical protein LOC202781
     241863_x_at CCDC39 1.74E-06 0.5 Coiled-coil domain-containing 39
  List of 50 classifi  er genes distinguishing SoJIA patients from healthy controls. Genes are grouped based on functional ontology. 
SoJIA classifi  er transcripts described above were next tested 
for their ability to discriminate SoJIA patients from patients 
with infections (31 patients with   Staphylococcus aureus  , 15 patients 
with   Streptococcus pneumoniae  , 30 patients with   Escherichia coli  , 
and 18 patients with infl  uenza A). As controls for noninfec-
tious disease and steroid treatment, we included a group of 
38 pediatric systemic lupus erythematosus (SLE) patients and 
6 patients with PAPA syndrome, an IL-1  –  mediated auto-
infl  ammatory disease. These 50 genes were also dysregulated 
in patients with infl  ammatory conditions, as 45% of   S. aureus  , 
47% of   S. pneumoniae  , 36% of   E  .   coli  , 5% of Infl  uenza A, 
29% of SLE, and 33% of PAPA syndrome patients were in-
correctly classifi  ed as SoJIA (  Fig. 2 B  ). Some of the genes 
included in the 50 best classifi  ers were mildly dysregulated 
in patients with established SoJIA and persistent arthritis, but 
not systemic symptoms (SoJIA 2) and in asymptomatic patients 
(SoJIA 3) (Fig. S1     A, available at http://www.jem.org/cgi/
content/full/jem.20070070/DC1). These patients, however, 
were correctly discriminated from the patients with systemic 
disease (Fig. S1 B). 
  Thus, the comparison of transcripts from SoJIA PBMCs 
and healthy controls is insuffi   cient to yield SoJIA-specifi  c 
  signatures. Furthermore, the blood transcription patterns of 
SoJIA patients during the systemic phase of the disease are closer 
to those of patients with infections than to those of SoJIA 
  patients in later (arthritic) stages of the disease. 
  Identifi  cation of a specifi  c SoJIA signature 
  To identify a diagnostic SoJIA signature, the transcription 
profi  les of SoJIA patients with systemic symptoms were di-
rectly compared with all the other infectious/infl  ammatory 
conditions. However, a large proportion of the predictor 
genes identifi  ed using this approach was found expressed 
similarly in SoJIA patients and healthy controls (unpublished 
data). Because it is diffi   cult to control potentially confound-
ing factors such as age or sex when comparing more than 
two groups of patients, we adopted a diff  erent strategy (see Fig. 
S2, available at http://www.jem.org/cgi/content/full/jem
.20070070/DC1, and reference   28   for details). First, we 
performed statistical comparisons between each group of 
patients (16 SoJIA, 16  S. aureus  , 10  S. pneumoniae  , 10 E.  coli  , 
10 infl  uenza A, and 16 SLE) and their respective control 
groups composed of age- and gender-matched healthy donors. 
The p-values obtained from each comparison were then 
subjected to selection criteria that permitted the identifi  ca-
tion of genes signifi  cantly changed in SoJIA patients versus 
their control group, and not in any of the other disease versus 
control groups. 
  A nonstringent statistical group comparison (nonpara-
metric Mann-Whitney rank test; P      0.01) between 16 SoJIA 
and 10 healthy control samples yielded 4,311 diff  erentially 
expressed transcripts (  Fig. 3 A  ).   88 of these transcripts were 
expressed with a p-value of     0.5 in all other diseases com-
pared with their corresponding healthy control groups (  Fig. 
3 B   and   Table II  ).   More than 50% of these genes (47/88) 
encode proteins with unknown function. Among those en-
coding known proteins, several are involved in microtubule/
cytoskeleton reorganization, ubiquitination, cellular transport, 
apoptosis, metabolism, transcription, protein biosynthesis, and 
posttranslational protein modifi  cation (  Table II  ). The gene 
tree corresponding to these diff  erentially expressed transcripts 
in individual patients and controls is displayed in   Fig. 3 C  . 
Only 1 of these 88 best classifi  ers (AK2) overlapped with the 
50 genes that best discriminated SoJIA patients from healthy 
controls (  Tables I and II  ), confi  rming the lack of specifi  city 
of our initial approach. 2136 DIAGNOSTIC SIGNATURES IN S  O  JIA BLOOD LEUKOCYTES | Allantaz et al.
and 6 new ones) and 12 SoJIA, 5   S. aureus  , 4   S. pneumoniae  , 
5   E. coli  , and 5 infl  uenza A patients (all from our initial 
  microarray study). The results of these experiments con-
fi  rmed that expression of these eight genes is signifi  cantly 
  To validate the microarray data, we selected the 8/88 
best-characterized genes based on their genomic sequence 
to perform RT-PCR. RNA samples were obtained from 
12 healthy controls (6 from our initial microarray analysis 
  Figure 3.     SoJIA-specifi  c signature. (A) Genes expressed at statistically different levels in the SoJIA patient group compared with healthy volunteers 
(P      0.01; Wilcoxon-Mann-Whitney test) were selected (4,311 probe sets). p-values were similarly obtained from patients suffering from S.   aureus , 
S.   pneumoniae  , E.   coli ,  infl  uenza A, and SLE. Each of these cohorts was compared with the corresponding control group. p-values are represented according 
to color scale: turquoise, low p-value; pink, high p-value. (B) 88/4,311 transcripts were found expressed at statistically different levels in the SoJIA patient 
group compared with healthy controls (P      0.01; Wilcoxon-Mann-Whitney test), but not in all of the other groups compared with their healthy controls 
(P      0.5; Wilcoxon-Mann-Whitney test). (C) The 88 genes from B were hierarchically clustered in the 107 samples used in the meta-analysis. Expression 
values of those 88 genes were normalized per gene to the healthy group. (D) The 12 most signifi  cant genes (P      0.0001 in SoJIA group) were used as 
  predictors for an independent test set of 10 healthy patients, 9 patients with febrile syndromes to rule out the diagnosis of SoJIA (2 of these patients were 
later on found to suffer from other diseases), 15 S.   aureus  , 5 S.   pneumoniae  , 20 E.   coli  , 8 infl  uenza A, 22 SLE, and 6 PAPA syndrome patients. Expression 
values of those 12 genes were normalized per gene to the healthy group. Genes were arranged by hierarchical clustering. Transformed expression levels are 
indicated by color scale, with red representing relative high expression and blue indicating relative low expression. The list of the 88 and 12 genes shown in 
B  –  D is displayed in Table II. (E) The 12 gene signature displayed in D is shown in 16 healthy controls, 23 samples from 19 patients with established diagnosis 
of SoJIA while presenting systemic symptoms, and 11 patients with established diagnosis of SoJIA in whom the systemic symptoms had subsided but 
  arthritis persisted. Only one patient with confi  rmed clinical diagnosis of SoJIA did not display the signature while having systemic symptoms (*).     JEM VOL. 204, September 3, 2007 
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  To determine if a specifi  c cell type is preferentially con-
tributing to the overrepresentation of these transcripts, their 
expression was analyzed in B cells, T cells, monocytes, and 
neutrophils from healthy donors and SoJIA patients, as well 
as myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) from 
healthy donors. Interestingly, 5/12 transcripts showed the 
highest expression levels in mDCs (not depicted). Within the 
cells that we analyzed, expression of CLIC-2 is restricted to 
this cell type (  Fig. 4, A and B  ).   However, whether the 12 
transcript signature derives from a cell type not normally pre-
sent in the blood (i.e., a bone marrow precursor) needs to be 
ruled out. 
  Treatment with IL-Ra (Anakinra) partially extinguishes 
the SoJIA signature 
  The eff  ect of IL-1 blockade on the SoJIA-specifi  c signature 
was analyzed by comparing the expression of the 873 tran-
scripts that diff  erentiate SoJIA patients from healthy controls 
(  Fig. 1   and Table S2) in eight active SoJIA patients before 
and after initiation of IL-1 blockade. Anakinra was found 
to induce a signifi  cant change (P      0.05) in the expression 
levels of 389 transcripts. The 10 most signifi  cant are displayed 
in   Fig. 5  .   They include genes encoding proteins with anti-
apoptotic function (Pim-1) (  31  ), lysosomal ATP-ase activity 
(ATP6V0A1), Cdc42-binding proteins linked to F-actin 
  accumulation at the immunological synapse (Cdc42SE2) (  32  ), 
glutamate receptor (GRINA), MAP2 kinase 3 (MAP2K3), 
prohibitin (PHB), and the solute carrier protein family 
(SLC25A37). Of them, only MAP2K3 has a known poten-
tial link to IL-1, as this molecule has been shown to down-
modulate IL-1 responses on fi  broblast-like synoviocytes and 
to regulate p38 activation in experimental infl  ammatory ar-
thritis (  33, 34  ). 
  Only 19 of the 88 diagnostic transcripts described above 
(  Table II  ) overlapped with the 389 transcripts that signifi  -
cantly changed upon IL-1 blockade. Thus, the majority of 
transcripts that best diff  erentiate SoJIA patients from patients 
with other infl  ammatory conditions do not appear to be the 
target of IL-1. This is not surprising, as IL-1 plays an impor-
tant role in other diseases included in this analysis. Therefore, 
IL-1  –  related genes could have been counter-selected in our 
analysis of signifi  cance across diseases. 
    DISCUSSION   
  SoJIA is the only form of JIA in which systemic symptoms 
precede the appearance of joint infl  ammation. Because sys-
temic symptoms and current laboratory tests are nonspecifi  c, 
a major remaining challenge is how to establish the prompt 
diagnosis of the disease during the systemic phase to avoid 
lengthy hospitalizations and initiate eff  ective therapy. Here, 
we show that gene expression patterns in blood leukocytes 
may be used, together with careful clinical assessment, to dis-
criminate SoJIA during the systemic phase of the disease from 
other febrile conditions. 
  Patients with SoJIA display a very striking pattern of  leuko-
cyte gene transcription when compared with healthy controls. 
increased in SoJIA patients, but not in infections compared 
with healthy controls (Fig. S3, available at http://www.jem
.org/cgi/content/full/jem.20070070/DC1). 
  12 genes can be used to diagnose SoJIA 
  A more stringent analysis (P      0.0001) permitted us to iden-
tify 12/88 genes highly diff  erentially expressed in SoJIA com-
pared with healthy controls, but not diff  erentially expressed 
(P      0.5) in all other disease groups compared with their re-
spective controls. These 12 genes are included in   Table II  . 
  The ability of this set of 12 genes to identify patients with 
SoJIA was then validated using independent groups of pa-
tients and controls. A training set composed of 10 healthy and 
16 SoJIA samples was used to predict sample class for an in-
dependent test set composed of a random group of 10 healthy 
patients, 9 patients with fever of more than 10 d in duration 
and negative bacterial cultures (suspected to have SoJIA), and 
15   S. aureus  , 5   S. pneumoniae  , 20   E. coli  , 8 infl  uenza A, 22 SLE, 
and 6 PAPA syndrome patients (  Fig. 3 D  ). This analysis 
allowed us to accurately classify six out of seven patients ful-
fi  lling SoJIA clinical diagnostic criteria. The only SoJIA pa-
tient not accurately classifi  ed (Sys 99 in Table S1) had fever, 
rash, and arthritis at the time of blood draw and eventually 
responded well to treatment with steroids and methotrexate. 
Two additional patients who were not classifi  ed as SoJIA (Sys 
85 and Sys 91) were subsequently diagnosed with diff  erent 
diseases. Overall, 93% of S.   aureus  , 100% S.   pneumoniae  , 95% 
of E.   coli  , 91% of SLE, and 100% of infl  uenza A and PAPA 
syndrome samples were correctly discriminated from SoJIA 
(  Fig. 3 D  ). Thus, the   “  normalization  ”   of each patient group to 
healthy control values and the comparison of signifi  cances 
rather than expression levels permitted us to extract a signature 
unique to the majority of SoJIA patients. 
  The expression of the 12 transcripts was next tested in the 
11 SoJIA patients described above, in whom the systemic 
symptoms had subsided but continued to display arthritis. As 
shown in   Fig. 3 E  , 11/11 patients did not diff  erentially ex-
press these genes compared with healthy controls, further in-
dicating that this signature is specifi  c to the systemic phase of 
the disease. 
  Whether the dysregulated expression of these 12 genes 
is related to the pathogenesis of SoJIA remains to be deter-
mined. Overall, seven of these genes encode uncharacterized 
proteins. Among those encoding proteins with known func-
tion, the most signifi  cantly up-regulated transcript (average, 
8.2-fold), chloride intracellular channel 2 (CLIC-2), belongs 
to the ubiquitous glutathione transferase structural family. 
CLIC-2 is one of only a few cytosolic inhibitors of cardiac 
ryanodine receptor 2 channels and may suppress their activity 
during diastole and stress (  29  ). Interestingly, CLIC-2 is the 
only transcript encoding a protein with potential link to IL-1 
secretion, as chloride has been shown to play an important 
role in maintaining the P2X7 receptor (P2X7R) in a confor-
mationally restrained state. This in turn limits the coupling of 
this receptor to signaling pathways that regulate caspase 1 and 
IL-1b signaling cascade (  30  ). 2138 DIAGNOSTIC SIGNATURES IN S  O  JIA BLOOD LEUKOCYTES | Allantaz et al.
  Table II.  Best classifi  ers distinguishing SoJIA patients from infectious diseases, SLE, and PAPA 
  Probe set ID    Gene symbol    p-value   Average 
normalized 
values in 
SoJIA 
  Gene title 
Apoptosis       
     212373_at FEM1B 5.27E-04 0.7 Fem-1 homolog b (  Caenorhabditis     elegans  )
     235116_at TRAF1 9.06E-04 1.3 TNF receptor  –  associated factor 1
Extracellular matrix      
     202337_at PMF1 9.06E-04 0.7 polyamine-modulated factor 1
     216993_s_at COL11A2 0.00241 1.4 collagen, type XI,      2
Glycosylation       
     201724_s_at GALNT1 0.00462 0.9 UDP-  N  -acetyl-alpha-  D  -galactosamine:polypeptide   N  -
acetylgalactosaminyltransferase 1
     210205_at B3GALT4 5.27E-04 1.3 UDP-Gal:    GlcNAc      1,3-galactosyltransferase, polypeptide 4
Metabolism       
     209301_at CA2 0.00374 2.6 carbonic anhydrase II
     209509_s_at DPAGT1 0.0015 1.2 dolichyl-phosphate   N  -acetylglucosaminephosphotransferase 1
     212174_at AK2    a    8.80E-07 0.7 adenylate kinase 2
Microtubule/Cytoskeleton     
     200703_at DNCL1 2.16E-04 1.7 dynein, cytoplasmic, light polypeptide 1
     207490_at TUBA4 3.96E-04 1.4 tubulin,      4
Nuclear mRNA splicing, via spliceosome    
     223416_at SF3B14 0.00241 0.8 splicing factor 3B, 14 kD subunit
     225394_s_at MADP-1    a   2.62E-06 0.6 MADP-1  protein
Phosphorylation     
     211992_at WNK1 5.27E-04 2.1 WNK lysine  –  defi  cient protein kinase 1
     226979_at MAP3K2 0.00567 0.7 mitogen-activated protein kinase kinase kinase 2
     227073_at MAP3K2 0.00836 0.8 mitogen-activated protein kinase kinase kinase 2
Protein biosynthesis      
     212225_at SUI1 2.16E-04 0.6 putative translation initiation factor
     224302_s_at MRPS36 0.00374 0.8 mitochondrial ribosomal protein S36
     226296_s_at MRPS15    a    3.80E-05 0.6 mitochondrial ribosomal protein S15
Protein folding        
     201759_at TBCD 1.12E-04 2.2 tubulin-specifi  c chaperone d
     225061_at DNAJA4 0.00191 2.4 DnaJ (Hsp40) homolog, subfamily A, member 4
     228622_s_at DNAJC4    a    3.80E-05 0.7 DnaJ (Hsp40) homolog, subfamily C, member 4
Transcription       
     202484_s_at MBD2 0.00191 0.7 methyl-CpG  –  binding domain protein 2
     224099_at KCNH7 0.00191 1.5 potassium voltage-gated channel, subfamily H (eag-related), 
member 7
     224933_s_at JMJD1C 0.00374 0.7 jumonji domain-containing 1C
     225527_at CEBPG 0.00117 0.7 CCAAT/enhancer-binding protein (C/EBP),    
     227685_at TMF1 0.0069 0.8 TATA element modulatory factor 1
     228785_at ZNF281 0.00241 0.6 Zinc fi  nger protein 281
     235389_at PHF20 0.00462 0.8 PHD fi  nger protein 20
     35671_at GTF3C1 2.16E-04 1.3 general transcription factor IIIC, polypeptide 1,      220 kD
Transport       
     201066_at CYC1 5.27E-04 0.8 cytochrome c-1
     202125_s_at ALS2CR3 5.27E-04 2.1 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, 
candidate 3
     213415_at CLIC-2    a   1.69E-05 8.3 CLIC-2
     215716_s_at ATP2B1 0.00241 0.6 ATPase, Ca++ transporting, plasma membrane 1
     218211_s_at MLPH 0.00462 1.5 melanophilinJEM VOL. 204, September 3, 2007 
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  Table II.  Best classifi  ers distinguishing SoJIA patients from infectious diseases, SLE, and PAPA (Continued) 
  Probe set ID    Gene symbol    p-value   Average 
normalized 
values in 
SoJIA 
  Gene title 
     224787_s_at RAB18 6.94E-04 0.7 RAB18, member RAS oncogene family
     225352_at TLOC1    a    1.10E-05 2.4 translocation protein 1
     226154_at DNM1L 0.00836 0.8 Dynamin 1  –  like
     238066_at RBP7 0.00836 0.8 retinol binding protein 7, cellular
     244227_at SYT6 0.00241 1.3 synaptotagmin VI
Ubiquitination       
     200718_s_at SKP1A 0.00462 1.3 S-phase kinase  –  associated protein 1A (p19A)
     201824_at RNF14 0.00301 2 ring fi  nger protein 14
     210579_s_at TRIM10 0.00835 1.4 tripartite motif-containing 10
Unknown       
     211994_at WNK1    a   2.62E-06 2.8 WNK  lysine  –  defi  cient protein kinase 1
     212055_at C18orf10    a    5.54E-05 2 chromosome 18 open reading frame 10
     212341_at MGC21416 0.00836 1.6 hypothetical protein MGC21416
     212829_at   —  6.94E-04 2 CDNA FLJ13267 fi  s, clone OVARC1000964 
     216739_at   —  3.96E-04 1.6 CDNA: FLJ20874 fi  s, clone ADKA02818
     218116_at C9orf78 0.00191 2.1 chromosome 9 open reading frame 78
     218126_at FLJ10579 9.06E-04 1.5 hypothetical protein FLJ10579
     218583_s_at RP42 0.00462 1.5 RP42 homolog
     218936_s_at HSPC128 0.00117 0.6 HSPC128 protein
     222309_at C6orf62 0.00567 0.6 chromosome 6 open reading frame 62
     223112_s_at NDUFB10 3.96E-04 0.8 NADH dehydrogenase (ubiquinone) 1      subcomplex, 10, 22kDa
     223548_at C1orf26 0.0015 1.4 chromosome 1 open reading frame 26
     224807_at KIAA1533 0.0015 0.8 KIAA1533
     224915_x_at TALDO1 9.06E-04 0.7 transaldolase 1
     225202_at RHOBTB3 0.0069 1.2 Rho-related BTB domain containing 3
     225213_at TA-PP2C 2.16E-04 0.8 T cell activation protein phosphatase 2C
     225819_at TBRG1 0.00241 0.7 transforming growth factor      regulator 1
     226833_at FLJ32499 0.00301 1.3 hypothetical protein FLJ32499
     226927_at   —  0.00374 1.2 hypothetical protein LOC728568
     227265_at FGL2 0.00301 0.8 fi  brinogen-like 2
     228452_at C17orf39 0.00625 1.6 chromosome 17 open reading frame 39
     228953_at WHDC1    a    5.54E-05 0.6 WAS protein homology region 2 domain containing 1 
     229074_at EHD4 0.00117 0.8 EH domain  –  containing 4
     229653_at FLJ10979 0.00836 1.4 hypothetical protein FLJ10979
     230118_at   — 2.16E-04 1.3 transcribed  locus
     230421_at LOC345462 0.00567 1.2 similar to hypothetical protein 9630041N07
     230546_at VASH1    a   7.95E-05 1.6 vasohibin  1
     230747_s_at C18orf17    a    3.80E-05 0.7 chromosome 18 open reading frame 17
     232486_at LRFN1 0.00462 1.4 leucine-rich repeat and fi  bronectin type III domain  –  containing 1
     232709_at   —  0.00191 0.7 CDNA FLJ13427 fi  s, clone PLACE1002477
     233469_at psiTPTE22 0.00301 1.3 TPTE pseudogene
     234305_s_at MLZE 9.06E-04 1.4 melanoma-derived leucine zipper, extra-nuclear factor
     235798_at   — 0.00117 0.8   — 
     236196_at ZNF326 0.0015 0.7 CDNA FLJ42548 fi  s, clone BRACE3004996
     241491_at KIAA1002 6.94E-04 1.5 KIAA1002 protein
     241517_at DDEF1 0.00117 1.3 development and differentiation enhancing factor 1
     241817_at FLJ43654 3.96E-04 0.7 FLJ43654 protein
     242003_at LOC157697 0.00301 0.7 hypothetical protein LOC157697
     242300_at UBB 3  ’   UTR    a    2.56E-05 4 ubiquitin B (UBB) mRNA, 3  ’   UTR and genetic suppressor element2140 DIAGNOSTIC SIGNATURES IN S  O  JIA BLOOD LEUKOCYTES | Allantaz et al.
alterations in blood cell numbers similar to those of SoJIA 
patients. As age, gender, and time of day when the blood 
is drawn have been described to infl  uence blood gene expres-
sion patterns (  35  ), our samples were matched for age and 
gender with controls and most of them were obtained within 
similar time frames. 
  There was a signifi  cant degree of overlap between the 
signatures of SoJIA patients and all the other infl  ammatory 
disease groups included in this study, especially Gram (	) bac-
terial infections, further stressing the need for multi-cohort 
studies when searching for disease-specifi  c biomarkers. The 
overlap could be due to dysregulated cytokine production 
and/or signaling cascades that may be shared by some of 
these diseases. IL-1, for example, is important in the cascade of 
defense mechanisms against many bacterial infections (  36, 37  ). 
Increased IL-1b production has also been described in 
These diff  erences might refl  ect changes in blood cell composi-
tion, i.e., the presence of a cell population not normally found 
in the blood, or fl  uctuations in numbers of blood-specifi  c cell 
populations rather than real transcriptional changes. Active 
  SoJIA patients, for example, display increased platelet and 
  leukocyte numbers compared with healthy controls. Erythroid 
precursors, which are not normally present in peripheral 
blood, are also found in these patients, and erythroid-specifi  c 
transcripts are among the most signifi  cantly up-regulated in 
SoJIA blood. 
  To control for changes in cell composition and fi  nd a 
  SoJIA-specifi  c signature, we included in our analysis 138 
samples from pediatric patients with systemic infl  ammation, 
including bacterial and viral infections, autoimmune (SLE), 
and autoinfl  ammatory (PAPA) diseases. Some of these pa-
tients (i.e., bacterial infections and PAPA syndrome) display 
  Table II.  Best classifi  ers distinguishing SoJIA patients from infectious diseases, SLE, and PAPA (Continued) 
  Probe set ID    Gene symbol    p-value   Average 
normalized 
values in 
SoJIA 
  Gene title 
     243109_at MCTP2 2.94E-04 1.7 multiple C2-domains with two transmembrane regions 2
  List of 88 classifi  er genes distinguishing SoJIA patients from other infl  ammatory diseases. Genes are grouped based on functional ontology. 
   a  12  most  signifi  cant genes used in the prediction. 
  Figure 4.     Transcription of CLIC-2 in blood cell subsets. (A) Total RNA was extracted from the PBMCs of 16 healthy donors and 16 SoJIA patients; 
B cells, T cells, and monocytes from 3 healthy donors and 4 SoJIA patients, and neutrophils from 6 healthy donors and 7 SoJIA patients. Amplifi  ed cRNA was 
hybridized on Affymetrix HG-U133 chips. Raw intensity values from each chip were fi  rst pre-scaled to the 500 target intensity value in Affymetrix Micro-
array suite before being imported and analyzed in GeneSpring 6.1. (B) Total RNA was extracted from the PBMCs of 16 healthy donors and 16 SoJIA patients, 
mDCs from 9 healthy donors, and pDCs from 6 healthy donors. Amplifi  ed cRNA was hybridized to Affymetrix HG-U133 chips. Raw intensity values from 
each chip were pre-scaled to the 500 target intensity value in Affymetrix Microarray suite before being imported and analyzed in GeneSpring 6.1.     JEM VOL. 204, September 3, 2007 
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Using this approach, a SoJIA-specifi  c signature composed of 
88 genes was identifi  ed. This signature is very stable over 
time, as we could identify it in two samples from a patient 
obtained     2 yr apart (unpublished data). Using a more strin-
gent analysis (P      0.0001 in SoJIA and P      0.5 in all other 
groups), 12 highly signifi  cant genes permitted to accurately 
classify the disease in 18/19 SoJIA patients. Furthermore, it 
allowed us to rule out SoJIA in two febrile patients who later 
developed arthritis but proved to suff  er from diff  erent diseases. 
It also allowed us to discriminate systemic infections with 
Gram (+) and Gram (  −  ) bacteria in 48/50 patients. Perhaps 
more interesting, six out of six patients with PAPA syn-
drome were not classifi  ed as SoJIA. How this signature will 
perform in discriminating SoJIA patients from other auto-
infl  ammatory diseases where IL-1 is also dysregulated is 
currently being investigated. 
  Most of the genes included within the SoJIA-specifi  c sig-
nature encode proteins that remain uncharacterized. Of those 
that encode known proteins, we did not fi  nd any obvious 
components of the IL-1 pathway. As discussed above, this 
might be expected as IL-1 also plays an important role in the 
infl  ammatory response against some of the infectious diseases 
  autoinfl  ammatory diseases including PAPA syndrome. Indeed, 
PAPA patients display a mutation in the PSTPIP1 gene (  22  ) 
that exerts a dominant-negative eff  ect on the activity of pyrin 
and leads to increased IL-1b production by peripheral blood 
leukocytes (  16  ). Interestingly, the herein described blood 
transcription patterns of SoJIA patients during the systemic 
phase of the disease are closer to those of patients with infec-
tions than to those of SoJIA patients who have resolved the 
systemic phase but continue displaying active arthritis. This 
could be explained if diff  erent pathogenic events, i.e., diff  erent 
cytokine cascades, were responsible for the diff  erent phases 
of the disease. Alternatively, the same cytokine alteration in a 
more localized environment (i.e., the joint) may not give rise 
to a blood cell signature. 
  To identify a specifi  c blood signature that would permit 
the accurate diff  erential diagnosis of SoJIA patients during 
the systemic phase of the disease, we designed an analysis of 
signifi  cance across multiple febrile infl  ammatory diseases and 
control groups. One of the advantages of this analysis is that 
it permits us to normalize each disease group to its own 
matched control group, therefore avoiding biological (i.e., 
age, gender) or technical (i.e., array runs) confounding factors. 
  Figure 5.     Anakinra effect on the specifi  c SoJIA signature. Transcription levels (raw values) corresponding to the genes that best differentiate SoJIA 
patients from healthy controls (from Fig. 1 and Table S2) were analyzed before and after the initiation of Anakinra in eight patients. The 10 genes with 
most signifi  cant p-values are displayed (p-values were calculated using a paired, two-tailed   t   test).   2142 DIAGNOSTIC SIGNATURES IN S  O  JIA BLOOD LEUKOCYTES | Allantaz et al.
  S. pneumoniae   (3.1 yr; 2 mo  –  16 yr), 18 with infl  uenza A infections (1.5 yr; 
3 wk  –  16 yr), 38 patients with SLE (12 yr; 5  –  18 yr), and 6 patients with PAPA 
syndrome (32.6 yr; 11  –  68 yr). Patients were divided in training and test sets 
according to age and treatment (Table S1). Subjects were recruited at Texas 
Scottish Rite Hospital and Children  ’  s Medical Center of Dallas. Healthy 
controls included patients with hypermobility attending the rheumatology 
clinic and healthy children undergoing routine surgical procedures with no 
history of asthma, acute infections, or infl  ammatory conditions. Most of the 
samples were obtained between 9:00 a.m. and 12:00 p.m. The study was 
  approved by the Institutional Review Boards of UT Southwestern Medical 
Center, Texas Scottish Rite Hospital, and Baylor Health Care System, and 
informed consent was obtained from all patients (legal representatives and 
patients over 10 yr of age). Bacterial and viral infections were confi  rmed by 
standard bacterial cultures, direct fl  uorescent antigen testing, and viral cultures. 
Patients with infections were recruited once a confi  rmed microbiologic 
  diagnosis was established. Respiratory viral cultures were performed in 60 of 
73 (82%) patients with bacterial infections. The clinical and demographic 
characteristics of these patients are summarized in Table S1 and have been 
reported elsewhere (  41  ). PAPA syndrome patients were diagnosed based on 
clinical data and sequencing the PSTPIP1 gene. 
  RNA and microarray sample preparation from PBMC and blood cell 
subpopulations.     All blood samples were obtained in EDTA purple-top tubes 
(BD Vaccutainer). Fresh PBMCs were isolated via Ficoll gradient. Cells were 
lysed in RLT lysis buff  er containing     -mercaptoethanol (QIAGEN). 
  pDCs and mDCs were purifi  ed from a healthy donor  ’  s buff  y coats. Ficoll-
enriched PBMCs were depleted of lineage  	   cells with CD3, CD14, CD19, 
CD16, CD56, and glycophorin A microbeads (Miltenyi Biotec). After staining 
with lineage cocktail-FITC, CD11c-allophycocyanin, and CD123-PE (BD-
Biosciences), and HLA-DR-QR (Sigma-Aldrich) mAbs, cells were sorted on 
a FACSVantage (Becton Dickinson) to at least 99% purity. 
  Monocytes, B cells, and T cells were positively selected from PBMCs 
using CD14 microbeads, CD19 microbeads, or CD3 microbeads (Miltenyi 
Biotec) and MS column (Miltenyi Biotec) according to the manufacturer  ’  s 
instructions to at least 95% purity. Neutrophils were isolated from venous 
blood of healthy volunteers by dextran (GE Healthcare) sedimentation of 
erythrocytes and density gradient centrifugation of leukocytes. The resulting 
cell populations contained     2% contaminating cells. 
  Total RNA was isolated using the RNeasy kit (QIAGEN) according to 
the manufacturer  ’  s instructions, and the RNA integrity was assessed by using 
an Agilent 2100 Bioanalyzer (Agilent). For PBMCs and neutrophils, 5   
  g 
of total RNA was used to generate double-stranded cDNA containing the 
T7-dT (  24  ) promoter sequence (Operon) as a template for in vitro transcription 
single-round amplifi  cation with biotin labels, using the Enzo R BioArrayTm 
HighYieldTM RNA Transcript Labeling kit (Aff  ymetrix, Inc.). For the 
other cell subtypes, the same protocol was used starting with 50 ng of total 
RNA and performing two rounds of amplifi  cation. Biotinylated cRNA tar-
gets were purifi  ed using the Sample Cleanup Module (Aff  ymetrix, Inc.) and 
hybridized to human U133A and B GeneChips (Aff  ymetrix, Inc.) according 
to the manufacturer  ’  s standard protocols. Arrays were scanned using a laser 
confocal scanner (Agilent). 
  Microarray data analysis.     For each Aff  ymetrix U133A and B GeneChip, 
raw intensity data were normalized to the mean intensity of all measure-
ments on that array and scaled to a target intensity value of 500 (TGT) in 
Aff  ymetrix Microarray Suite 5.0. Data were then further analyzed using 
GeneSpring software version 7.0. Data were normalized to a set of healthy 
controls (sex- and age-matched). An Aff  ymetrix fl  ag of   “  present  ”   in at least 
75% of samples of each cohort designated the fi  lter of reliable intensity mea-
surement from each individual gene chip. The combined two lists (17,231 
probes) were used as quality control for statistical tests, class prediction, and 
clustering algorithms subsequently performed on the data. Class comparison 
was performed using nonparametric ranking statistical analysis test (Mann-
Whitney) applied to quality control genes. In the vertical direction, hierar-
chical clusters of genes were generated using the Spearman correlation. Class 
included in this study. IL-1  –  related genes would have there-
fore been counter-selected. CLIC-2, the most up-regulated 
of the 12 transcripts that compose the SoJIA-specifi  c signature, 
might be involved in the regulation of IL-1 secretion. This 
gene encodes a chloride channel, and chloride levels control 
the conformation of P2X7R (  30  ). This in turn limits the 
coupling of this receptor to signaling pathways that regu-
late caspase 1 and IL-1b signaling cascade. Interestingly, ex-
pression of CLIC-2 within PBMCs seems to be restricted to 
mDCs (  38  ). IL-1 amplifi  es DC function, and IL-1 production 
is induced when monocytes are co-cultured with alloreactive 
T cells and autologous DCs through a cell contact  –  dependent 
mechanism (  39  ). Studies are currently underway to determine 
whether these genes are up-regulated in SoJIA blood mDCs 
or in a diff  erent cell population not normally present in the 
blood of healthy and infected children. 
  Even though the clinical symptoms were controlled in 
the majority of SoJIA patients treated with an IL-1 receptor 
antagonist, expression of only a fraction (389/873) of the 
dysregulated transcripts returned to control levels in treated 
patients. Several explanations might be put forward to ex-
plain this observation. IL-1 could be downstream of a factor 
present in SoJIA serum that is not blocked by Anakinra. In-
deed, the residual SoJIA signature might be a tool to identify 
such an IL-1  –  inducing factor. The IL-1 antagonist eff  ect of 
Anakinra may be suffi   cient to silence the clinical symptoms, 
but not to erase the molecular signature. Finally, our limited 
patient sample before and after Anakinra treatment may not 
be enough to give statistical power to this analysis, and more 
patients may need to be studied to draw fi  rm conclusions. 
  The small number of genes identifi  ed in this study as 
  SoJIA-specifi  c might help in the diagnosis of patients with 
febrile conditions included under the term   “  fever of unknown 
origin.  ”   They might also allow to promptly initiate specifi  c 
therapy in SoJIA patients even before arthritis develops, thus 
avoiding the need for additional therapies and the develop-
ment of long-term disabilities. The identifi  cation of genes 
whose expression is restored back to normal levels upon 
successful IL-1 blockade might also help identify predictors 
of response to therapy in longitudinal studies. 
  SoJIA patients are heterogeneous, however, regarding 
  severity of symptoms and disease course (  38, 40  ). Further 
studies will therefore be required to confi  rm the value of 
blood gene transcription profi  ling in establishing the diagno-
sis and predicting the response to IL-1 blockade in larger 
patient cohorts. 
  MATERIALS AND METHODS 
  Patient information.     Blood samples were obtained from 21 patients with 
clinical diagnosis of SoJIA (4 patients were tested twice at an interval of 
1  –  2 yr) during the systemic phase of the disease (median age, 6 yr; range, 
2  –  17 yr). In two patients, subsequent clinical course ruled out this diagnosis. 
Samples were from 11 patients with SoJIA in the arthritis phase of the disease, 
14 asymptomatic patients, and 8 patients with SoJIA treated with Anakinra 
(6 yr, 2  –  19 yr). These were also analyzed together with 94 patients hospitalized 
with active infections: 30 patients with   E. coli   infection (1 yr; 2 wk  –  16 yr), 
31 patients with   S. aureus   infection (7 yr; 3 mo  –  18 yr), 15 patients with JEM VOL. 204, September 3, 2007 
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prediction was performed using a supervised learning algorithm, K-Nearest 
Neighbors Method, that assigns a sample to predefi  ned classes in three steps: 
(a) identifi  cation of genes that have strong correlations to parameters (pre-
defi  ned classes) of a training set of samples; (b) determination of an estimate 
of prediction error rates of training set by a leave-one-out cross-validation 
method; and (c) validation with an independent test set to obtain a true pre-
diction error rate. In step 1, the Fisher exact test is used to identify genes by 
their degree of correlation to the predefi  ned class (by user) of the training set 
of samples. Genes are then ranked by their predictive strength (negative nat-
ural log of p-value) that represents the probability of obtaining the observed 
number of samples from each class above or below the ideal pattern by 
chance. In step 2, samples from the training set are clustered using the k-NN 
method, where neighbors are identifi  ed by representing gene expression as 
vectors and placing samples according to the Euclidean distance. Each gene  ’  s 
discriminative ability is considered equally regardless of its value determined 
by Fisher  ’  s exact test (i.e., each classifi  er   “  votes  ”   for a cohort and each vote 
is equal). After each gene evaluates the sample, the votes are summed to de-
termine classifi  cation of the sample. Leave-one-out cross validation estimates 
the prediction error rate (or accuracy) by the systematic removal of one do-
nor from the training set to use as a test sample. This process is repeated until 
all the donors have been   “  tested.  ”   A p-value ratio cutoff   of 0.2 was used in 
all discrimination analyses. A p-value ratio of 0.2 (equivalent to 1/5) indi-
cates that the algorithm will make a prediction if the p-value (probability that 
the test sample is predicted as belonging to one class by chance) of the fi  rst 
best class is at least fi  ve times smaller than the p-value of the next best class. 
If the actual p-value ratio is less than the cutoff  , a prediction will be made; if 
the ratio is higher, no prediction will be made. Setting the p-value cutoff   
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an independent sample set is evaluated, as in step 2, except for the leave-
one-out cross-validation estimates. 
  For the comparison between PBMCs and cell subtypes, Aff  ymetrix 
U133A and B GeneChip raw intensity data were scaled to a target intensity 
value of 500 (TGT) in Aff  ymetrix Microarray Suite 5.0. Data were then im-
ported into Genespring and analyzed without any further normalization steps. 
  RT-PCR.     RNA samples were DNase treated with TURBO DNA-free kit 
(Ambion), and total RNA for RT-PCR analysis was further amplifi  ed due 
to low yields of total RNA. 5 
g of each RNA sample was converted to 
cDNA using the High Capacity cDNA Archive kit (Applied Biosystems) in 
the PerkinElmer GeneAmp PCR System 9600. Quantitative PCR was per-
formed on selected targets using pre-developed primers and probe TaqMan 
Gene Expression Assays (Applied Biosystems) on the ABI Prism 7700 Se-
quence Detection System. Expression results were calculated as the diff  er-
ence in cycle threshold relative to the median of four healthy volunteers for 
each target confi  rmed. 
  Online supplemental material.     Fig. S1 shows the diff  erential gene ex-
pression profi  les in PBMCs from healthy controls and SoJIA patients at three 
diff  erent stages of disease. Fig. S2 shows the analysis scheme that was fol-
lowed to identify a SoJIA-specifi  c signature. Fig. S3 shows the validation of 
the discriminative value of selected genes by RT-PCR. Table S1 shows the 
patient clinical data, and Table S2 shows a list of 873 genes distinguishing 
SoJIA patients from healthy controls. The online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20070070/DC1. 
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